Haisco Pharmaceutical Group (SHE:002653) said its HSK39297 tablets were officially included in China's list of breakthrough therapy drugs by the Center for Drug Evaluation.
The drug is indicated for the treatment of primary IgA nephropathy, a kidney disease, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments